Literature DB >> 7999239

The menace of substandard drugs.

J Roy1.   

Abstract

Numerous small pharmaceutical manufacturers in Bangladesh are marketing substandard drugs, often deliberately using inadequate levels of active ingredients. Stricter application of the national drug policy is necessary, notably in regard to the issuing of licences and the sanctions applied to firms breaking the law.

Mesh:

Substances:

Year:  1994        PMID: 7999239

Source DB:  PubMed          Journal:  World Health Forum        ISSN: 0251-2432


  6 in total

Review 1.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

2.  In-vitro evaluation of the quality of paracetamol and co-trimoxazole tablets used in Malawi based on pharmacopoeial standards.

Authors:  Felix Khuluza
Journal:  Malawi Med J       Date:  2014-06       Impact factor: 0.875

3.  The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999.

Authors:  Lamphone Syhakhang; Cecilia Stålsby Lundborg; Björn Lindgren; Göran Tomson
Journal:  Pharm World Sci       Date:  2004-12

Review 4.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Diffusion of counterfeit drugs in developing countries and stability of galenics stored for months under different conditions of temperature and relative humidity.

Authors:  Francesca Baratta; Antonio Germano; Paola Brusa
Journal:  Croat Med J       Date:  2012-04       Impact factor: 1.351

6.  Establishment of galenic laboratories in developing countries to produce high quality medicines: results of Aid Progress Pharmacist Agreement (A.P.P.A.®) Project.

Authors:  Francesca Baratta; Antonio Germano; Gaetano Di Lascio; Richard Petieau; Paola Brusa
Journal:  Croat Med J       Date:  2014-12       Impact factor: 1.351

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.